secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2024-07-17T23:59:59+00:00
Accession:  0000200406-24-000071
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

J&J Q2 revenue up 4.3% but GAAP EPS falls 5.9%; adjusted EPS rises 10.2%
------------------------------------------------------------------------

- Q2 2024 revenue $22.4B, +4.3% YoY; GAAP diluted EPS $1.93, -5.9% YoY; adjusted diluted EPS $2.82, +10.2% YoY.
- Innovative Medicine (ex-COVID) revenue $14.3B, +6.5% operational; MedTech revenue $7.96B, +2.2% reported.
- GAAP net earnings from continuing ops $4.69B, -12.8% YoY, impacted by $194M IPR&D impairments and prior-year gains.
- Adjusted net earnings from continuing ops $6.84B, +1.6% YoY; effective tax rate up to 18.5% from 14.7%.
- Share repurchase reduced diluted share count to 2,422M from 2,626M YoY, boosting adjusted EPS growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000020040624000071/0000200406-24-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000020040624000071/jnj-20240717.htm
  HTML page:      https://secwatch.observer/filing/0000200406-24-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer